drugset / Trial / NCT00004163
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Phase 2
Completed
14 enrolled
Dana-Farber Cancer Institute
Genentech, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have advanced salivary gland cancer.
Timeline
- Start
- 1999-10
- Primary completion
- 2001-09
- Completion
- 2001-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |